ABO-incompatible marrow transplants.
We analyzed data from 81 ABO-incompatible marrow transplants performed between 1972 and 1980. Patients with high anti-red blood cell antibody levels pretransplant had a significantly increased probability of antibody return post-transplant. This was true for IgG and for IgM as independent variables. However, the return of antibody post-transplant had no effect on engraftment, survival, or blood product requirements posttransplant. Patients who received ABO-incompatible marrow had a similar time to engraftment, survival, and incidence of rejection and graft-versus-host disease as patients receiving ABo-compatible transplants. Neither pretransplant treatment regimen nor the development of graft-versus-host disease had an effect on post-transplant antibody levels. ABO-incompatible marrow transplants can be performed with no greater morbidity or mortality than ABO-compatible grafts. The procedures for antibody removal may be useful in other organ transplant settings.
D000017:ABO Blood-Group System / Q000276:immunology*; D001787:Blood Group Incompatibility / Q000150:complications* / Q000401:mortality / Q000628:therapy; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D017707:Erythrocyte Transfusion; D005078:Exchange Transfusion, Whole Blood; D006084:Graft Rejection; D006461:Hemolysis; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007163:Immunosorbent Techniques; D010951:Plasma Exchange; D017713:Platelet Transfusion
D000017:ABO Blood-Group System; D007074:Immunoglobulin G; D007075:Immunoglobulin M